Kornimate/medical-research-clean huggingface dataset:
the effect of hyaluronic acid gel on relieving post-implantation pain

Conditions: Implant Complication

Summary: few previous studies have employed ha in the implant socket; instead, the majority have applied it topically to the area around dental implants after they have been placed. the application was done after suturing in these investigations. therefore, the goal of the current study was to inject ha into the implant socket and onto the alveolar bone prior to implant insertion and suturing in order to preserve the ha for an extended period of time. this study aims to use a visual analog scale (vas) on the first, third, and tenth days following the surgical intervention to assess the efficacy of employing ha in dental implants in terms of pain reduction that may accompany dental implant surgery.


Eligibility criteria:
inclusion criteria: * bilateral tooth loss with a sufficient amount of bone volume * no general problems * good oral health * age between 20 and 60 years exclusion criteria: * the use of immunosuppressive drugs and corticosteroids for long periods * the existence of serious systemic disorders * contraindications for local anesthesia or oral surgery * pregnant women and nursing mothers * patients receiving chemotherapy or radiation * alcoholics and heavy smokers.
etsf for latinx young adults with alcohol use disorder

Conditions: Alcohol Use Disorder (AUD)

Summary: the goal of this clinical trial is to learn if the etsf intervention is feasible among latinx young adults with alcohol use disorder. the main questions it aims to answer are: * is etsf feasible? * is etsf effective in reducing alcohol use and increasing 12-step engagement compared to the control condition? the control condition will receive educational materials on drinking problems and a list of local/online aa meetings participants will * be randomly assigned to either the etsf condition or the control condition. * fill out the baseline online survey. * go through the etsf app/control materials. * and at 3 months post-baseline, fill out the follow-up online survey.


Eligibility criteria:
inclusion criteria: * yas age 18-29 * identify as latinx * meet the diagnostic \& statistical manual of mental disorders 5th edition (dsm-5) diagnostic criteria for alcohol use disorder * are at least minimally motivated to change their drinking (i.e., scoring ≥3 on the university of rhode island change assessment scale's contemplation, action, or maintenance subscales and ≤3 on the precontemplation subscale) * be able to provide at least one contact person to assist in tracking them for follow-up assessment exclusion criteria: * attending any 12-step program (≥2 meetings in the past month) * experiencing psychotic symptoms or cognitive impairment * in alcohol or drug treatment programs * taking addiction treatment medications * experiencing, expecting to experience, or had a history of severe/complicated withdrawal
effect of intravitreal ranibizumab injection with retinal vein occlusion (rvo)

Conditions: Macular Edema; Retinal Vein Occlusion

Summary: the purpose of this study is to evaluate the effects of intravitreal lucentis® (ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein occlusion (rvo).


Eligibility criteria:
inclusion criteria: * signed written informed consent * patients with macular edema due to rvo (confirmed by fundus photography, fluorescein angiography, oct) * male and female aged from 18 to 70 * baseline best-corrected visual acuity (bcva) in the study eye was from 20/400 to 20/30 using etdrs chart exclusion criteria: * additional eye disease that could compromise va * ocular inflammation * intraocular surgery ≤ 1 month before day 0 * uncontrolled glaucoma * prior treatments with laser photocoagulation or other intervention for macular edema due to brvo * patients aged under 18 or over 71 * female patient in pregnancy or breast feeding * not suitable to regular follow up
differentiation of pseudoprogression and true progression through high field susceptibility weighted imaging and r2*

Conditions: Radiation Injury; Radiation Necrosis

Summary: using a multi-echo gradient echo sequence to calculate r2\* and quantitative susceptibility maps and well as susceptibility-weighted imaging post processing the investigators hypothesize that the investigators would be able to distinguish between pseudoprogression and true progression with the use of an easily implementable sequence on clinical mri scanners.

post-treatment radiographic imaging change (ptric) is seen in approximately 50% of patients who are treated for brain neoplasms using chemotherapy and radiotherapy. ptric can be attributed to true disease progression or a form of benign radiographic enhancement, known in literature as pseudoprogression. of these patients, 50% of them have benign radiographic enhancement that is usually spontaneously resolved and required no intervention. the other 50% require immediate medical intervention, or more aggressive treatment for true progression. currently standard medical practise is to administer a prophylactic treatment of chemotherapy to all patients with ptric with a follow up scan 3-6 months after initial ptric diagnosis, leading to up to 50% of patients receiving an unneeded dose of chemotherapy. the investigators hope to take advantage of the differentiation in tissue types and vascularization between true progression tumour and pseudoprogression to be able to identify patients who would not need to be administered a prophylactic dose of chemotherapy.

Eligibility criteria:
inclusion criteria: 1. the subject must consent to participate. 2. the subject must be above the age of 18. 3. patients must be classified as possible pseudoprogression or true progression 4. patients scoring \>= 70 on the karnofsky performance status. exclusion criteria: 1. any subject with contraindication to an mri procedure as listed in the magnetic resonance environment screening questionnaire. 2. any subject who may be unable to tolerate the mri environment due to physical size and/or known tendency to claustrophobia. 3. any subject who does not expect to be available to attend the for the required study mri scans 4. patients scoring \< 70 on the karnofsky performance status. 5. attending radiation oncologist or neurologist determines patient is no longer able to consent for themselves.

Keywords: radiation injury radiation necrosis ultra-high field mri susceptibility weighted imaging post-treatment radiographic imaging change
stone disease of the urinary tract in children

Conditions: Urinary Lithiasis

Summary: the incidence of stone disease of the urinary tract in children is increasingly increasing with a remarkable economic impact for its management. this incidence is variable according to race, geographic region, socio-economic status and dietary habits. oxalo-calcium stones are the most common but the biochemical nature of urinary stones varies depending on the region where those of a phosphatic nature are characterized by a higher incidence in europe. the diagnosis is confirmed by imaging. the unprepared abdomen (asp) has low diagnostic accuracy. the scanner is the reference tool but remains an irradiating examination. risk factors for disease recurrence include primarily the presence of an underlying urinary metabolic abnormality and young age. urinary metabolic abnormalities vary from one study to another. the understanding of lithogenesis, its evaluation as well as the therapeutic options is essential for adequate and adapted management in the pediatric population.


Eligibility criteria:
inclusion criteria: * patients aged less than 18 years. * both sexes. * subjects presenting with lithiasis of the urinary tree in one of the two departments concerned between 01/01/2010 and 12/31/2022 * subject not opposing, after information, the reuse of their data for the purposes of this research. * holders of parental authority who do not object, after being informed, to the reuse of their child's data for the purposes of this research. exclusion criteria: * subject or holder of parental authority having expressed opposition to participating in the study. * non-usable patient files: insufficient data.

Keywords: urinary lithiasis stone disease urolithiasis urinary calculi
sonographic predictors of difficult epidural placement.

Conditions: Anesthesia; Safety Issues; Epidural; Anesthesia, Headache

Summary: epidural placement is a commonly used procedure for pain management during labor, delivery, and surgeries. however, epidural placement is often considered a technically challenging and complex procedure that requires a high level of skill and experience. in cases where the epidural is improperly placed or fails to produce effective analgesia, the discomfort and distress experienced by the patient may be heightened. hence, the use of predictors, such as sonographic ones, may prove to be a valuable tool for healthcare professionals in the placement of epidurals, ultimately ensuring successful pain management for patients. the present study aims to identify predictors of difficult epidural placement in patients undergoing surgery.


Eligibility criteria:
inclusion criteria: * surgery with epidural placement * age \> 18 years exclusion criteria: * patient refusal

Keywords: technique epidural predictors placement
autonomic cardiovascular control in response to blood volume reduction in blood donors

Conditions: Autonomic Dysfunction; Autonomic Imbalance; Blood Loss

Summary: the function of the autonomic nervous system can be assessed using baroreflex sensitivity (brs) and heart rate variability (hrv). decreased hrv has been shown to be predictive of morbidity and mortality in diverse medical conditions such as acute myocardial infarction, aneurysmal subarachnoid haemorrhage, autoimmune diseases, sepsis and surgery. the function of the autonomic nervous system has not yet been investigated in a "pure hypovolemia" model. the aim of the current study is therefore to investigate and describe the function of the autonomic nervous system prior to, during and after reduction of blood volume in healthy blood donors.


Eligibility criteria:
inclusion criteria: * volonteers eligable for blood donation following the danish legislation * male * age 30-45 * written informed consent * speak and understand danish exclusion criteria: volonteers not eligable for blood donation following the danish legislation, among others due to: * alcohol and drug abuse * cognitive dysfunction * use of anxiolytic or antipsychotic drugs * arrhythmias or heart failure * diabetes mellitus type i * diabetes mellitus type ii * use of opioids * history of following diseases in the autonomic nervous system: parkinson disease, multiple sclerosis, autonomic neuropathies * history of cerebral apoplexy or transitory cerebral ischemia * dementia * american society of anesthesiologists (asa) score ≥ 4 furthermore: * history of orthostatic intolerance and/or orthostatic hypotension * use of following vasodilator antihypertensive drugs: beta-blockers, angiotensin converting enzyme inhibitors (acei), angiotensin 2 receptor blockers (arbs), calcium channel blockers * use of loop diuretics, thiazid diuretics and potassium-sparing diuretics

Keywords: heart rate variabilty baroreceptor sensitivity autonomic nervous system acute blood loss blood donors autonomic cardiovascular control
degarelix before radical prostatectomy

Conditions: Prostate Cancer

Summary: the biological effects of castration on prostate cancers will be studies by administration of degarelix prior to radical prostatectomy. the effects will be studied by analysis of gene expression and immunohistochemistry focusing on markers of proliferation and apoptosis of samples taken at the time of radical prostatectomy (7 days after administration of degarelix). tumours from patients treated with neo-adjuvant degarelix will be compared with tumours from patients who have not been medically castrated.


Eligibility criteria:
inclusion criteria: * intermediate/high risk prostate cancer * patient eligible for and wanting surgery exclusion criteria: * inability to consent * previous thromboembolism/arrhythmias * contraindication to degarelix or surgery

Keywords: prostate cancer testosterone castration degarelix proliferation
psychosocial support to facilitate the return to employment of women with breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to compare the effect of early individualized psychosocial assets versus a standard support on social inequalities in the rate of return to work

for the group "intervention", patients have four interviews with a psychologist (at cure one of chemotherapy treatment, at cure six of chemotherapy treatment, at last radiotherapy session, and three months after the end of radiotherapy). in the 2 arms, patients receive 4 sets of questionnaires (baseline, month 12, month 18 and month 24)

Eligibility criteria:
inclusion criteria: * women ≥ 18 with work at the time of diagnosis * presenting a unilateral breast cancer exclusively local extension * having received surgery * reporting of adjuvant chemotherapy (+ / - trastuzumab) * reporting to radiotherapy or not (if radiotherapy, it will be done on site investigator) * in work at the time of diagnosis (employees, traders and professionals) * patient affiliated to a social security scheme * consent signed by the patient before the implementation of any specific procedure to study exclusion criteria: * presence of in situ lesions, cancer recurrence, metastatic disease immediately, location bilateral * inability physical, psychological, psychiatric or cognitive responses to the questionnaires and participate in interviews * recognition previous ald (due to another disease) * patient under guardianship
solo and non-solo approach for laparoscopic appendectomy (soloap)

Conditions: Appendicitis; Laparoscopic

Summary: to determine the safety and feasibility of solo laparoscopic appendectomy, which is defined as the application of solo surgery to laparoscopic appendectomy, by comparing consecutive non-solo procedures conducted by a surgeon in the presence or absence of human assistant(s).

laporoscopic appendectomy usually requires three surgeons, including an operator, a camera assistant, and other instrument assistant. recent advancement of technology made it possible to develop the conveniently adjustable holders for camera and other laparoscopic instruments. the application of these instruments enables "solo-surgery" wherein an operation is driven by single surgeon. during surgery, human assistant(s) are helpful because of their instant assistance according to the operation's need. therefore, the utilization of instruments instead of human assistants would be cumbersome. however, the utilization of instruments would be helpful by enabling operation-driven repositioning of the camera and instrument(s). currently, no attempt has been made to objectively compare the merits and demerits of these two procedures. therefore, this study was conducted to determine the safety and feasibility of solo laparoscopic appendectomy, which is defined as the application of solo surgery to laparoscopic appendectomy, by comparing consecutive non-solo procedures conducted by a surgeon in the presence or absence of human assistant(s).

Eligibility criteria:
inclusion criteria: 1. the patients planned to undergo elective laparoscopic appendectomy 2. benign gallbladder diseases requiring surgery 3. the patients who are indicated for single-port laparoscopic appendectomy. exclusion criteria: 1. the patients with complicated cholecystitis 2. the patients with the gallbladder with a thickness more than 4mm. 3. the patients who are expected to have severe peritoneal adhesion. 4. the patients with malignant gallbladder diseases. 5. the patients whose operation appears to need human assistant(s)

Keywords: solo surgery camera holder laparoscopic appendectomy
a clinical study that will assess the effect of sep-363856 or prior antipsychotic (pa) standard of care on body-weight associated parameters in subjects with schizophrenia

Conditions: Schizophrenia

Summary: a clinical study that will look at an investigational medication, sep-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters. this study is accepting male and female participants age 18 years to 65 years. this study will be conducted in approximately 6 study sites in the united states. participation could last up to 13 weeks.

this is a double-blind, randomized, multiple dose study in male and female adult subjects with schizophrenia. subjects will undergo structural magnetic resonance abdominal imaging (mri) scans as well as hyperinsulinemic euglycemic clamp (hec) also known as "glucose clamp", after the check-in and towards the end of the treatment phase. subjects will be randomized to sep-363856 or their prior antipsychotic (pa). subjects randomized to sep-363856 will undergo blinded wash out of their pa, subsequent sep-363856 blinded titration and 15 day of well tolerated sep-363856 exposure. subjects randomized to their prior antipsychotic (pa), will undergo pseudo pa washout, followed by pseudo-titration and 15 day of well tolerated pa exposure. subjects will be discharged after subject is stable. all subjects will return to the clinic 7 + 2 days post discharge for follow-up assessments.

Eligibility criteria:
inclusion criteria: this is not an all inclusive list * male or female subjects between 18 and 65 years of age, inclusive at time of consent. * subject meets diagnostic and statistical manual of mental disorders (dsm-5) criteria for a primary diagnosis of schizophrenia as established by clinical interview, using the dsm-5 as a reference and confirmed using the structured clinical interview for dsm-5, clinical trials version \[scid-ct\]). * subject must have a positive and negative symptoms scale (panss) total score ≤ 80 at screening and a score of ≤ 4 on the following panss items at screening: p7 (hostility) and g8 (uncooperativeness) * subject must have a clinical global impressions - severity (cgi-s) score ≤ 4 (normal to moderately ill) at screening. * subject must be receiving risperidone, olanzapine, quetiapine or aripiprazole as treatment for schizophrenia at the time of screening. exclusion criteria: this is not an all inclusive list * subject has a dsm-5 diagnosis or presence of symptoms consistent with a dsm-5 diagnosis other than schizophrenia or intellectual disability (iq \< 70). * subject has attempted suicide within 12 months prior to screening. * subject answers "yes" to "suicidal ideation" items 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the c-ssrs at screening (ie. in the past 1 month) or at any subsequent c-ssrs assessment prior to dosing (ie, since last visit). * subject is at risk of harming him/herself or others according to the investigator's judgment.
development study of pain monitoring and injury impact scale

Conditions: Sports Injuries; Social Impact; Psychological Impact of Injury

Summary: this study introduced and validated the pain monitoring and injury impact scale for athletes (pamiis), developed to address the lack of a comprehensive tool in turkish for assessing injury-related pain and its multidimensional impact on athletes.the development process involved expert consultations, literature review, and feedback from athletes, resulting in a 37-item pool that was refined through pilot testing. psychometric analyses conducted with 148 athletes demonstrated strong internal consistency, high test-retest reliability, and substantial correlations with established tools such as the visual analog scale, ostrc-o, and ostrc-h. the final scale structure, consisting of 32 items across four subscales, was confirmed through both exploratory and confirmatory factor analyses. pamiis is a psychometrically sound instrument for systematically monitoring athletes' health status and documenting the short- and long-term consequences of sports injuries.

abstract aims: in turkish, there is no valid and reliable measurement tool for monitoring the health status of athletes and evaluating the effects of injuries on them from various dimensions. with this study, we aimed to develop a measurement tool to detect pain associated with sports injuries and to investigate the consequences of injury. we created a measurement tool called pain monitoring and injury impact scale for athletes-pamiis, which consists of a pain detection diagram and an injury impact scale. methods: pamiis was designed and improved upon expert, partner, and participant opinions and a literature review. initially, a pool of 37 items was created. the content and scope of the tool were checked with a pilot test on 30 athletes. in the main test phase, 148 participants (200 sample) were tested for item consistency, and 55 athletes (70 sample) were retested for stability to determine reliability. for concurrent validity, pamiis sub-scores were compared with the visual analog scale, the oslo sports trauma research center overuse injury questionnaire (ostrc-o), and the oslo sports trauma research center on health problems (ostrc-h) scores. scale structure revealed with exploratory factor analysis (efa) for the construct validity. in the final phase, 90 (122 sample) athletes were administered the restructured scale, and its construct was tested with confirmatory factor analysis (cfa).

Eligibility criteria:
inclusion criteria: * engaged in regular participation in any form of sporting activity for a minimum duration of six months * aged 13 years or older * had sufficient proficiency in the turkish language to comprehend and respond to the study materials * voluntarily agreed to participate in the study, with informed consent obtained exclusion criteria: * pregnancy or illiteracy

Keywords: pain monitoring scale development performance participation
study of novel types of familial diabetes insipidus

Conditions: Diabetes Insipidus

Summary: objectives: i. define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (fdi) in kindreds with atypical or novel forms of fdi.

protocol outline: participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (di). the studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of ddavp. if clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed. linkage analysis is performed for all participants; kindreds with the marfan-like syndrome are also studied for the fibrillin-1 genotype. participants determined to have di are treated with desmopressin for 2 days.

Eligibility criteria:
* familial diabetes insipidus (di) in atypical or novel form, e.g.: dipsogenic di neurohypophyseal di * affected and unaffected members of kindreds eligible

Keywords: diabetes insipidus endocrine disorders rare disease